All contributors
Onconephrology contributor
Dong, Zheng
Primarily Anticancer drug nephrotoxicity#13 of 47 recognizedHonor roll
- #1 in Anticancer drug nephrotoxicity
31
Clinical papers
3,041
Citations (iCite)
0 / 28
First / senior author
2006–2026
Active years
Output over time
Clinical corpus papers per year — peak 3 in 2008.
- 2006: 1 paper
- 2008: 3 papers
- 2009: 1 paper
- 2011: 1 paper
- 2013: 1 paper
- 2014: 1 paper
- 2015: 3 papers
- 2016: 2 papers
- 2017: 2 papers
- 2018: 3 papers
- 2019: 1 paper
- 2020: 1 paper
- 2021: 2 papers
- 2022: 2 papers
- 2023: 3 papers
- 2024: 2 papers
- 2025: 1 paper
- 2026: 1 paper
20062026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
Anticancer drug nephrotoxicity29
MGRS & paraprotein kidney disease2
Agents they study
Catalog agents whose clinical kidney literature lists Dong among the leading contributors.
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,329-article corpus (regenerated 2026-08-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.